A1EA becomes an eligible organisation of the European Medicines Agency (EMA)
The European Medicines Agency (EMA) officially confirmed that A1EA meets all the criteria to become an eligible patients’ and consumers’ organisation, marking an important milestone in the Alliance’s development and recognition at the European level.
Advancing care for children with Alpha-1: ERN RARE-LIVER AATD Working Group develops new paediatric guidance
International experts unite in Lyon, France, to strengthen diagnosis, treatment, and follow-up standards for children affected by Alpha-1 Antitrypsin Deficiency liver disease
Alpha-1 Europe Alliance launches its Scientific Advisory Board
The Alpha-1 Europe Alliance marks a key milestone with the launch of its Scientific Advisory Board (SAB), marking an important milestone in strengthening scientific collaboration and ensuring that the patient voice remains at the centre of advances in Alpha-1 Antitrypsin Deficiency (AATD).
European organisations join forces to strengthen the Alpha-1 patient voice in research and care
The European Alpha-1 community is coming together through a new initiative supported by the European Lung Foundation (ELF), European Alpha-1 Research Collaboration (EARCO), Alpha-1 Europe Alliance, Alpha-1 UK and Alpha1 Deutschland e.V. The initiative aims to strengthen awareness, research, diagnosis and care for people living with Alpha-1 Antitrypsin Deficiency (AATD) across Europe.
Alpha-1 Europe Alliance at IPPC 2026
Representatives of the Alpha-1 Europe Alliance participated in the International Plasma Protein Congress 2026, held in Milan, Italy, from 28–29 April, joining over 350 stakeholders from across the global plasma community.
Hosted by the Plasma Protein Therapeutics Association, this leading annual congress brought together industry leaders, policymakers, healthcare professionals, donors, and patient advocates to exchange insights and strengthen collaboration across the plasma-derived medicinal products (PDMPs) ecosystem.
The Alpha-1 Europe Alliance calls for equitable access to diagnosis and care at the European Parliament
Ahead of the European Alpha-1 Awareness Day on 25 April, the Alpha-1 Europe Alliance (A1EA) organised a high-level event at the European Parliament on 22 April 2026. The event brought together patients, policymakers, clinicians, researchers, and industry experts to discuss progress and ongoing challenges in the care and treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Alpha-1 Europe Alliance holds its 4th Annual General Assembly & Members Meeting
The Alpha-1 Europe Alliance (A1EA) held its Annual General Assembly and Members Meeting on 18 April 2026 in Warsaw, bringing together member organizations, clinicians, researchers, and industry partners from across Europe in a hybrid format. The meeting served as a key moment to reflect on progress, share knowledge, and strengthen collaboration across the Alpha-1 Antitrypsin Deficiency (AATD) community.
The Missing Piece: The new European campaign to reveal the invisible in Alpha-1 Antitrypsin Deficiency
On European Alpha-1 Awareness Day, the Alpha-1 Europe Alliance brings the community together to raise awareness and improve understanding of AATD across Europe.
Strengthening our voice in Europe: new Alpha-1 representatives join ERN-LUNG ePAG
The Alpha-1 community continues to strengthen its presence at European level with the formal acceptance of new representatives into the ePAG of ERN-LUNG in January 2026. Three new Alpha-1 representatives — Marion Wilkens (Germany), Ron Ewals (Netherlands) and Edwin Brekelmans (Netherlands) — have been formally accepted into the European Patient Advocacy Group (ePAG) of ERN-LUNG.
Plasma supply: a European strategic vulnerability
Alpha-1 Europe Alliance participated in the 4th biennial joint Symposium on Plasma Collection and Supply organized by the International Plasma and Fractionation Association IPFA and the European Blood Alliance EBA, held in the University Hall of Leuven, Belgium on 11-12 February 2026.